Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP284535.RAlsKaO2D_kjILnluZgyztSmb_XLPzaYLv0s5TreTEn24130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP284535.RAlsKaO2D_kjILnluZgyztSmb_XLPzaYLv0s5TreTEn24130_assertion type Assertion NP284535.RAlsKaO2D_kjILnluZgyztSmb_XLPzaYLv0s5TreTEn24130_head.
- NP284535.RAlsKaO2D_kjILnluZgyztSmb_XLPzaYLv0s5TreTEn24130_assertion description "[Finally, gemcitabine treatment of control animals and p48-Cre/LSL-Kras(G12D) animals with pancreatic cancer caused distinct and up to 60-fold changes in circulating miRs that indicate differential drug effects on normal and cancer tissues.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP284535.RAlsKaO2D_kjILnluZgyztSmb_XLPzaYLv0s5TreTEn24130_provenance.
- NP284535.RAlsKaO2D_kjILnluZgyztSmb_XLPzaYLv0s5TreTEn24130_assertion evidence source_evidence_literature NP284535.RAlsKaO2D_kjILnluZgyztSmb_XLPzaYLv0s5TreTEn24130_provenance.
- NP284535.RAlsKaO2D_kjILnluZgyztSmb_XLPzaYLv0s5TreTEn24130_assertion SIO_000772 21738581 NP284535.RAlsKaO2D_kjILnluZgyztSmb_XLPzaYLv0s5TreTEn24130_provenance.
- NP284535.RAlsKaO2D_kjILnluZgyztSmb_XLPzaYLv0s5TreTEn24130_assertion wasDerivedFrom befree-20140225 NP284535.RAlsKaO2D_kjILnluZgyztSmb_XLPzaYLv0s5TreTEn24130_provenance.
- NP284535.RAlsKaO2D_kjILnluZgyztSmb_XLPzaYLv0s5TreTEn24130_assertion wasGeneratedBy ECO_0000203 NP284535.RAlsKaO2D_kjILnluZgyztSmb_XLPzaYLv0s5TreTEn24130_provenance.